Sign in Subscribe
Drugs

Research Breakthroughs from Sahlgrenska University, Sweden

Strategic Insights

— 1 min read

Researchers at Sahlgrenska University, Sweden have made significant discoveries in the fields of immunology, cardiology, and oncology, shedding light on new treatment options and mechanisms for various diseases. These breakthroughs highlight the ongoing efforts of the university to push the boundaries of medical research and advance the field of healthcare.

Key Takeaways:

  • A study published in the Annals of Allergy, Asthma & Immunology found that rush immunotherapy modifies the immunologic response to allergen exposure, affecting the production of interleukin-12 by monocytes and interferon-gamma by natural killer cells. The study concluded that the restoration of cytokine imbalance by immunotherapy is not limited to the adaptive immune system but also extends to the innate immune system.
  • Researchers at Sahlgrenska University Hospital in Goteborg conducted a study on the inflammatory response in acute coronary syndromes (ACS), finding that plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6), and secretory phospholipase A2 group IIA (sPLA2-IIA) were significantly related to disease severity. The study also highlighted the complexity of the inflammatory response in ACS.
  • Another study published in Acta Oncologica explored the antiangiogenic effects of metronomic chemotherapy, finding that certain agents, such as cyclophosphamide and paclitaxel, exhibit significant dose-dependent antiangiogenic effects, while others, like doxorubicin, have minimal effects.

Statistics:

  • The proportion of IL-12+ monocytes increased by 3 months of rush immunotherapy (p=.003).
  • Patients in Killip class II-IV had higher levels of CRP and sPLA2-IIA compared to those in Killip class I (p.05).

Sources:

  • Plewako, H. et al. "Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy." Annals of Allergy, Asthma & Immunology, vol. 97, no. 4, 2006, pp. 464-468.
  • Hartford, M. et al. "CTRP, interleukin-6, secretory phospholipase A(2) group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up." International Journal of Cardiology, vol. 108, no. 1, 2006, pp. 55-62.
  • Albertsson, P. et al. "On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGF-A." Acta Oncologica, vol. 45, no. 2, 2006, pp. 144-155.

Read more